The origin and pathogenic consequences of anti-dsDNA antibodies in systemic lupus erythematosus

References

• Cervera R, Khamashta MA, Font J et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore)82(5), 299–308 (2003).
   PubMed Web of Science ®Google Scholar
• Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum.25(11), 1271–1277 (1982).
   PubMed Web of Science ®Google Scholar
• Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum.40(9), 1725 (1997).
   PubMed Web of Science ®Google Scholar
• Johnson AE, Gordon C, Palmer RG, Bacon PA. The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth. Arthritis Rheum.38(4), 551–558 (1995).
   PubMed Web of Science ®Google Scholar
• Cervera R, Khamashta MA, Font J et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore)72(2), 113–124 (1993).
   PubMed Web of Science ®Google Scholar
• Winfield JB, Faiferman I, Koffler D. Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus. Association of high avidity antinative DNA antibody with glomerulonephritis. J. Clin. Invest.59(1), 90–96 (1977).
   PubMed Web of Science ®Google Scholar
• Okamura M, Kanayama Y, Amastu K et al. Significance of enzyme linked immunosorbent assay (ELISA) for antibodies to double stranded and single stranded DNA in patients with lupus nephritis: correlation with severity of renal histology. Ann Rheum Dis.52(1), 14–20 (1993).
   PubMed Web of Science ®Google Scholar
• ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum.33(5), 634–643 (1990).
   PubMed Web of Science ®Google Scholar
• Krishnan C, Kaplan MH. Immunopathologic studies of systemic lupus erythematosus. II. Antinuclear reaction of γ-globulin eluted from homogenates and isolated glomeruli of kidneys from patients with lupus nephritis. J. Clin. Invest.46(4), 569–579 (1967).
   PubMed Web of Science ®Google Scholar
• Ehrenstein MR, Katz DR, Griffiths MH et al. Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. Kidney Int.48(3), 705–711 (1995).
   PubMed Web of Science ®Google Scholar
• Forger F, Matthias T, Oppermann M, Becker H, Helmke K. Clinical significance of anti-dsDNA antibody isotypes: IgG/IgM ratio of anti-dsDNA antibodies as a prognostic marker for lupus nephritis. Lupus13(1), 36–44 (2004).
   PubMed Web of Science ®Google Scholar
• Manson JJ, Mauri C, Ehrenstein MR. Natural serum IgM maintains immunological homeostasis and prevents autoimmunity. Springer Seminars in Immunopathology26(4), 425–432 (2005).
   PubMedGoogle Scholar
• Amoura Z, Koutouzov S, Chabre H et al. Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases: antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus. Arthritis Rheum.43(1), 76–84 (2000).
   PubMed Web of Science ®Google Scholar
• Radic MZ, Weigert M. Genetic and structural evidence for antigen selection of anti-DNA antibodies. Ann. Rev. Immunol.12(1), 487–520 (1994).
   PubMed Web of Science ®Google Scholar
• Rahman A, Giles I, Haley J, Isenberg D. Systematic analysis of sequences of anti-DNA antibodies – relevance to theories of origin and pathogenicity. Lupus11(12), 807–823 (2002).
   PubMedGoogle Scholar
• Mason L, Lambrianides A, Haley J et al. Stable expression of a recombinant human antinucleosome antibody to investigate relationships between antibody sequence, binding properties, and pathogenicity. Arthritis Res. Ther.7(5), R971–R983 (2005).
   Google Scholar
• Izui S, Lambert PH, Miescher PA. Failure to detect circulating DNA – anti-DNA complexes by four radioimmunological methods in patients with systemic lupus erythematosus. Clin. Exp. Immunol.30(3), 384–392 (1977).
   PubMed Web of Science ®Google Scholar
• Rumore PM , Steinman CR. Endogenous circulating DNA in systemic lupus erythematosus. Occurrence as multimeric complexes bound to histone. J. Clin. Invest.86(1), 69–74 (1990).
   PubMed Web of Science ®Google Scholar
• Amoura Z, Piette JC, Chabre H et al. Circulating plasma levels of nucleosomes in patients with systemic lupus erythematosus: correlation with serum antinucleosome antibody titers and absence of clear association with disease activity. Arthritis Rheum.40(12), 2217–2225 (1997).
   PubMed Web of Science ®Google Scholar
• Licht R, van Bruggen MC, Oppers-Walgreen B, Rijke TP, Berden JH. Plasma levels of nucleosomes and nucleosome-autoantibody complexes in murine lupus: effects of disease progression and lipopolyssacharide administration. Arthritis Rheum.44(6), 1320–1330 (2001).
   PubMed Web of Science ®Google Scholar
• Simon JA, Cabiedes J, Ortiz E, Alcocer-Varela J, Sanchez-Guerrero J. Anti-nucleosome antibodies in patients with systemic lupus erythematosus of recent onset. Potential utility as a diagnostic tool and disease activity marker. Rheumatology43(2), 220–224 (2004).
   PubMedGoogle Scholar
• Laderach D, Koutouzov S, Bach JF, Yamamoto AM. Concomitant early appearance of anti-ribonucleoprotein and anti-nucleosome antibodies in lupus prone mice. J. Autoimmun.20(2), 161–170 (2003).
   PubMedGoogle Scholar
• Bruns A, Blass S, Hausdorf G, Burmester GR, Hiepe F. Nucleosomes are major T and B cell autoantigens in systemic lupus erythematosus. Arthritis Rheum.43(10), 2307–2315 (2000).
   PubMedGoogle Scholar
• Ghirardello A, Doria A, Zampieri S et al. Antinucleosome antibodies in SLE: a two-year follow-up study of 101 patients. J. Autoimmun.22(3), 235–240 (2004).
   PubMedGoogle Scholar
• Cervera R, Vinas O, Ramos-Casals M et al. Anti-chromatin antibodies in systemic lupus erythematosus: a useful marker for lupus nephropathy. Ann Rheum Dis.62(5), 431–434 (2003).
   PubMed Web of Science ®Google Scholar
• Suer W, Dahnrich C, Schlumberger W, Stocker W. Autoantibodies in SLE but not in scleroderma react with protein-stripped nucleosomes. J. Autoimmunity22(4), 325–334 (2004).
   PubMed Web of Science ®Google Scholar
• Kramers C, Hylkema MN, van Bruggen MC et al. Anti-nucleosome antibodies complexed to nucleosomal antigens show anti-DNA reactivity and bind to rat glomerular basement membrane in vivo. J. Clin. Invest.94(2), 568–577 (1994).
   PubMed Web of Science ®Google Scholar
• Hylkema MN, van Bruggen MC, ten Hove T et al. Histone-containing immune complexes are to a large extent responsible for anti-dsDNA reactivity in the Farr assay of active SLE patients. J. Autoimmun.14(2), 159–168 (2000).
   PubMedGoogle Scholar
• Weening JJ, D’Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J. Am. Soc. Nephrol.15(2), 241–250 (2004).
   PubMed Web of Science ®Google Scholar
• Kaplan JM, Kim SH, North KN et al. Mutations in ACTN4, encoding α-actinin-4, cause familial focal segmental glomerulosclerosis. Nat.Genet.24(3), 251–256 (2000).
   PubMed Web of Science ®Google Scholar
• Yao J, Le TC, Kos CH et al. α-actinin-4-mediated FSGS: an inherited kidney disease caused by an aggregated and rapidly degraded cytoskeletal protein. PLoS Biology2(6), e167 (2004).
   PubMedGoogle Scholar
• Deocharan B, Qing X, Lichauco J, Putterman C. α-actinin is a cross-reactive renal target for pathogenic anti-DNA antibodies. J. Immunol.168(6), 3072–3078 (2002).
   PubMed Web of Science ®Google Scholar
• Mostoslavsky G, Fischel R, Yachimovich N et al. Lupus anti-DNA autoantibodies cross-react with a glomerular structural protein: a case for tissue injury by molecular mimicry. Eur. J. Immunol.31(4), 1221–1227 (2001).
   PubMed Web of Science ®Google Scholar
• Mason LJ, Ravirajan CT, Rahman A, Putterman C, Isenberg DA. Is α-actinin a target for pathogenic anti-DNA antibodies in lupus nephritis? Arthritis Rheum.50(3), 866–870 (2004).
   PubMedGoogle Scholar
• Zhao Z, Weinstein E, Tuzova M et al. Cross-reactivity of human lupus anti-DNA antibodies with α-actinin and nephritogenic potential. Arthritis Rheum.52(2), 522–530 (2005).
   PubMedGoogle Scholar
• Ravirajan CT, Rowse L, MacGowan JR, Isenberg DA. An analysis of clinical disease activity and nephritis-associated serum autoantibody profiles in patients with systemic lupus erythematosus: a cross-sectional study. Rheumatology (Oxford)40(12), 1405–1412 (2001).
   PubMedGoogle Scholar
• Kramers C, Termaat RM, ter Borg EJ et al. Higher anti-heparan sulphate reactivity during systemic lupus erythematosus (SLE) disease exacerbations with renal manifestations; a long term prospective analysis. Clin. Exp. Immunol.93(1), 34–38 (1993).
   PubMed Web of Science ®Google Scholar
• Faaber P, Rijke TP, van de Putte LB, Capel PJ, Berden JH. Cross-reactivity of human and murine anti-DNA antibodies with heparan sulfate. The major glycosaminoglycan in glomerular basement membranes. J. Clin. Invest.77(6), 1824–1830 (1986).
   PubMed Web of Science ®Google Scholar
• Termaat RM, Assmann KJ, van Son JP et al. Antigen-specificity of antibodies bound to glomeruli of mice with systemic lupus erythematosus-like syndromes. Lab. Invest.68(2), 164–173 (1993).
   PubMedGoogle Scholar
• Amital H, Heilweil M, Ulmansky R et al. Treatment with a laminin-derived peptide suppresses lupus nephritis. J. Immunol.175(8), 5516–5523 (2005).
   PubMed Web of Science ®Google Scholar
• Zack DJ, Stempniak M, Wong AL, Taylor C, Weisbart RH. Mechanisms of cellular penetration and nuclear localization of an anti-double strand DNA autoantibody. J. Immunol.157(5), 2082–2088 (1996).
   PubMed Web of Science ®Google Scholar
• Vlahakos D, Foster MH, Ucci AA et al. Murine monoclonal anti-DNA antibodies penetrate cells, bind to nuclei, and induce glomerular proliferation and proteinuria in vivo. J. Am. Soc. Nephrol.2(8), 1345–1354 (1992).
   PubMed Web of Science ®Google Scholar
• Clynes R, Dumitru C, Ravetch JV. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science279(5353), 1052–1054 (1998).
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Watanabe N, Akikusa B et al. Fc receptor-independent development of autoimmune glomerulonephritis in lupus-prone MRL/lpr mice. Arthritis Rheum.48(2), 486–494 (2003).
   PubMedGoogle Scholar
• Wang Y, Hu Q, Madri JA et al. Amelioration of lupus-like autoimmune disease in NZB/W F1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc. Natl Acad. Sci. USA93(16), 8563–8568 (1996).
   PubMed Web of Science ®Google Scholar
• Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J. Exp. Med.179(4), 1317–1330 (1994).
   PubMed Web of Science ®Google Scholar
• Mevorach D, Zhou JL, Song X, Elkon KB. Systemic exposure to irradiated apoptotic cells induces autoantibody production. J. Exp. Med.188(2), 387–392 (1998).
   PubMed Web of Science ®Google Scholar
• Botto M, Dell’ Agnola C, Bygrave AE et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat. Genet.19(1), 56–59 (1998).
   PubMed Web of Science ®Google Scholar
• Cohen PL, Caricchio R, Abraham V et al. Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase. J. Exp. Med.196(1), 135–140 (2002).
   PubMed Web of Science ®Google Scholar
• Napirei M, Karsunky H, Zevnik B et al. Features of systemic lupus erythematosus in Dnase1-deficient mice. Nat. Genet.25(2), 177–181 (2000).
   PubMed Web of Science ®Google Scholar
• Bickerstaff MC, Botto M, Hutchinson WL et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat. Med.5(6), 694–697 (1999).
   PubMed Web of Science ®Google Scholar
• Emlen W, Niebur J, Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J. Immunol.152(7), 3685–3692 (1994).
   PubMed Web of Science ®Google Scholar
• Herrmann M, Voll RE, Zoller OM et al. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum.41(7), 1241–1250 (1998).
   PubMed Web of Science ®Google Scholar
• Licht R, Dieker JW, Jacobs CW, Tax WJ, Berden JH. Decreased phagocytosis of apoptotic cells in diseased SLE mice. J. Autoimmun.22(2), 139–145 (2004).
   PubMed Web of Science ®Google Scholar
• Laderach D, Bach JF, Koutouzov S. Nucleosomes inhibit phagocytosis of apoptotic thymocytes by peritoneal macrophages from MRL+/+ lupus-prone mice. J. Leukoc. Biol.64(6), 774–780 (1998).
   PubMedGoogle Scholar
• Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ. Crystal structure of the nucleosome core particle at 2.8 A resolution.Nature389(6648), 251–260 (1997).
   PubMed Web of Science ®Google Scholar
• Amoura Z, Chabre H, Bach JF, Koutouzov S. Antinucleosome antibodies and systemic lupus erythematosus. Adv. Nephrol. Necker Hosp26, 303–316 (1997).
   PubMedGoogle Scholar